The ASCO Genitourinary (ASCO GU) and the Annual ASCO meetings are the leading educational and scientific events for oncologists, urologists, and the cancer team, providing the latest clinical and scientific data from clinical trials and basic and translational research in GU cancer. Thousands of abstracts summarizing state-of-the-art treatment modalities and novel therapies for patients with Prostate Cancer will be presented and it will be critical that educational programing provide learners with not only key data, but interpretation by faculty as to how best to incorporate into clinical practice.
Early Treatment Intensification in the Continuum of Prostate Cancer Care
Early Treatment Intensification in the Continuum of Prostate Cancer Care
Welcome to CME on ReachMD. This episode is part of our MinuteCE curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
Hi, I'm Dan George, GU Medical Oncologist, Professor of Medicine Surgery, and Director of GU Oncology at Duke Cancer Institute. And I'm joined by my good friend and colleague, Dr. Fred Saad from Montreal. Fred, you want to introduce yourself?
Sure. So I'm Professor and Chairman of Urology, and Director of GU Oncology at the University of Montreal Hospital Center, and glad to be with you again, Dan.
Fantastic, fantastic. Well, we are post ASCO, just trying to unpackage all the fantastic data that was presented. And of course, we have our top-line oral abstracts and all. But there was some interesting findings as well, buried in those poster sessions. And for those of you either not present there or who were there, but missed it, there were some – I think, really some really interesting findings there that I think help frame some of the ongoing studies of the day.
I want to talk, Fred, about surgery, about prostatectomy, and about the work that's going on around neoadjuvant therapy for prostatectomy. We've been at this game for a long time, docetaxel and other things. But in this era of novel hormonal agents and AR pathway inhibitors in particular, it seems like we're re-evaluating every paradigm of the past. Walk us through some of the - a couple of the abstracts there that we saw and posters that we saw that I think really caught your eye in terms of what we might be able to expect now in treating patients with these potent hormonal inhibitors pre-prostatectomy.
Right. So like you said, we've been at this for over 20 years, trying to improve our outcome with surgery through neoadjuvant, but we're basically giving only standard ADT with relatively low chances of reaching that P0, or pathological complete response when we do the surgery. And although we looked like we were improving surgical margin rates, the outcomes in terms of PSA recurrence didn't look like it made any difference whether or not patients got a few months of ADT prior to surgery. But this was in an era where we only had ADT. And now we're in an era where we can do much better, where we see tremendous PSA declines to undetectable, even in metastatic disease when we start combining ADT with these novel hormonal therapies like apalutamide and others that have been tested.
And so that is being tested in a very large randomized study, the PROTEUS study, looking at 6 months of ADT plus or minus apalutamide, followed by 6 months of ADT plus apalutamide after surgery in very high-risk patients. And we're still going to be waiting for that data for some time.
But we've got some data that was presented at ASCO looking at, you know, this intensification approach prior to surgery, plus or minus 18 months of therapy. And we're seeing that, you know, when you really give intensive therapy prior to surgery, you might not need to give much more. And so that's really been interesting. And it's forcing us to revisit the concept of whether or not we can do better than surgery alone in an era where we have therapies that are much more effective. And I think it's building on a wealth of work that's been going on in trying to do better in these patients that historically we would maybe only send to radiation therapy where they would get 2 or 3 years of ADT, and maybe we can do even better through surgery. Not to say surgery is better than radiation therapy.
Oh, come on now, you can say it.
Or radiation resistant, Dan, and we need to maybe sometimes get that out.
Yeah, I think you're absolutely right. And look it, I mean, I think surgery is still the gold standard for local control. And the truth is, is that if we can get by with 6 months of therapy, hormonal therapy, get people off of treatment, and be able to have that kind of clear pathologic reading and, you know, undetectable PSA to follow, that's attractive to a lot of patients, particularly our younger patients. And so the sort of definitive nature of that treatment is it's nice to have options for these people.
And, you know, I think, you know, radiation can learn from surgery, and maybe we won't need 2 years of hormonal therapy in everybody with radiation therapy. There was actually a nice oral presentation by Andy Armstrong from the NRG Group, showing an AI approach to predicting who needs 2 years of hormones versus a shorter course. And so there may be some tools in the future for, you know, who needs, you know, not just intensification but long-term intensification versus short-term intensification.
And this sort of story showing that the post-surgery adjuvant didn't necessarily make that big a difference is really interesting, that that wasn't randomized, that was sort of patient, you know, personal preference and whatnot. So, I think we have to be, you know, careful. There was some randomization, but there wasn't, you know, enough numbers, a lot of patients opted out of that. So I think we will need some future studies.
But there is a phase 3 study going on that is looking in this space around neoadjuvant and adjuvant hormonal therapy and surgery. Tell us about the PROTEUS study.
Yeah, so this is taking, you know, patients that historically would really have little chance of curing with surgery. You know, these are not just simply high risk, these are very high-risk patients. And patients are randomized to getting ADT alone versus ADT plus apalutamide 6 months prior and 6 months after the surgery. And I've got several patients on those, and not a single one has failed yet, even though we're in the follow-up phase. So I'm very impressed. I'm very, you know - I'm being cautious. I don't know who's getting a placebo, because the added adverse events of apalutamide over the ADT is very hard to figure out who's on a placebo and who's on ADT in the early setting. And so it's encouraging in terms of adverse events.
But it's extremely encouraging in terms of what I'm seeing in terms of pathological response and what I'm seeing in terms of PSA control, now that patients have completed and are still being followed, and testosterone has recovered. As long as it hasn't recovered, we can't really claim success. And so this is interesting, and we're very much looking forward to that.
And we saw some inklings of control with more intensive, shorter treatment with the with the FORMULA-509 study that was presented few months ago where patients failing surgery that are high risk, getting 6 months of apalutamide and ADT and radiation, were doing really, really well. Very comparable to the 2 years that the RADICALS study had to give to patients with salvage radiation. So I think the field is moving towards less but more intense.
Yes, less and more. I like it. All right. Well, thanks so much for the interesting discussion, Fred, as always appreciate it.
You have been listening to CME on ReachMD. This activity is jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc. and is part of our MinuteCE curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/CME. Thank you for listening.
This activity has been designed to meet the educational needs of the interprofessional team, including Medical Oncologists, Urologists, Nurses, Pharmacists as well as other clinicians involved in the management of patients with prostate cancer.
After participating in this educational activity, participants should be better able to:
- Apply recent practice-changing data to inform sequencing decisions and treatment strategies for patients with prostate cancer
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Daniel J. George, MD, faculty for this educational event, is a contracted researcher for Astellas, AstraZeneca, Bayer H/C Pharmaceuticals, BMS, Calithera, Exelixis, Inc, Janssen, Novartis, Pfizer, and Sanofi; and receives consulting fees from Novartis, Astellas, AstraZeneca, AVEO Pharmaceuticals, Bayer Pharmaceuticals, Brown and James Atty, Eisa, Exelixis, Inc, IdeoOncology, Janssen, Medscape Education, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences, Inc, Nektar Therapeutics, Pfizer, Propella TX, Sanofi, Seattle Genetics, UroGPO, UroToday WebMD, WilmerHale and Xcures.
Fred Saad, MD, FRCS, faculty for this educational event, is a contracted researcher for Astellas, AstraZeneca, Bayer, Janssen, Myovant, Pfizer, Novartis/AAA, Point, BMS, and Sanofi; and receives consulting fees from Astellas, Astrazeneca, Bayer, Janssen, Myovant, Pfizer, Novartis/AAA, Point, BMS, Tolmar, and Abbvie.
The following planners/reviewers/managers have disclosed:
Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.
William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.
TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.
All the relevant financial relationships for these individuals have been mitigated.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
This activity is supported by independent educational grants from Bayer and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
This activity is FREE to all participants.
During the period 3/3/2023 through 3/3/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.